Netra Unni Rajesh

Netra Unni Rajesh

Auto-generated profile, based on publicly available information

Netra Unni Rajesh

Department of Bioengineering, Stanford University, CA 94305, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 May 2022 in Science Advances
Verified
Journal Article
Open access
AKAmeya R. Kirtane
Ameya R. Kirtane
Christina KaravasiliChristina Karavasili
Christina Karavasili
AWAniket Wahane
Aniket Wahane
DFDylan Freitas
Dylan Freitas
KBKatelyn Booz
Katelyn Booz
GTGiovanni Traverso
Giovanni Traverso
Administering medicines to 0- to 5-year-old children in a resource-limited environment requires dosage forms that circumvent swallowing solids, avoid on-field reconstitution, and are thermostable, cheap, versatile, and taste masking. We present a strategy that stands to solve this multifaceted problem. As many drugs lack adequate water solubility, our formulations used oils, whose textures could be modified with gelling agents to form “oleogels.” In a clinical study, we showed that the oleogels can be formulated to be as fluid as thickened beverages and as stiff as yogurt puddings. In swine, oleogels could deliver four drugs ranging three orders of magnitude in their water solubilities and two orders of magnitude in their partition coefficients. Oleogels could be stabilized at 40°C for prolonged durations and used without redispersion. Last, we developed a macrofluidic system enabling fixed and metered dosing. We anticipate that this platform could be adopted for pediatric dosing, palliative care, and gastrointestinal disease applications.

26 February 2025 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
AKAmeya R. Kirtane
Ameya R. Kirtane
JBJianling Bi
Jianling Bi
NRNetra U. Rajesh
Netra U. Rajesh
CTChaoyang Tang
Chaoyang Tang
MJMiguel Jimenez
Miguel Jimenez
GTGiovanni Traverso
Giovanni Traverso

2 September 2024 in Advanced Materials
Verified
Journal Article
Open access
NRNetra U. Rajesh
Netra U. Rajesh
JHJihyun (Luna) Hwang
Jihyun (Luna) Hwang
YXYue Xu
Yue Xu
MSMax A. Saccone
Max A. Saccone
AHAndy H. Hung
Andy H. Hung
JDJoseph M. DeSimone
Joseph M. DeSimone
Using high‐resolution 3D printing, a novel class of microneedle array patches (MAPs) is introduced, called latticed MAPs (L‐MAPs). Unlike most MAPs which are composed of either solid structures or hollow needles, L‐MAPs incorporate tapered struts that form hollow cells capable of trapping liquid droplets. The lattice structures can also be coated with traditional viscous coating formulations, enabling both liquid‐ and solid‐state cargo delivery, on a single patch. Here, a library of 43 L‐MAP designs is generated and in‐silico modeling is used to down‐select optimal geometries for further characterization. Compared to traditionally molded and solid‐coated MAPs, L‐MAPs can load more cargo with fewer needles per patch, enhancing cargo loading and drug delivery capabilities. Further, L‐MAP cargo release kinetics into the skin can be tuned based on formulation and needle geometry. In this work, the utility of L‐MAPs as a platform is demonstrated for the delivery of small molecules, mRNA lipid nanoparticles, and solid‐state ovalbumin protein. In addition, the production of programmable L‐MAPs is demonstrated with tunable cargo release profiles, enabled by combining needle geometries on a single patch.

26 September 2025 in Science Advances
Verified
Journal Article
Open access
AHAndy H. Hung
Andy H. Hung
NKNetra U. Kamat
Netra U. Kamat
ABAbel Bermudez
Abel Bermudez
SBStephanie M. Boczek
Stephanie M. Boczek
FGFernando García-Marqués
Fernando García-Marqués
JDJoseph M. DeSimone
Joseph M. DeSimone
Dermal interstitial fluid (ISF) offers a promising alternative to invasive blood tests and opportunities for skin diagnostics. Progress in both the understanding and adoption of ISF tests is hindered by sampling challenges, including lengthy collection times, non-negligible failure rates, variable collection volumes, and inconsistent bioanalyte levels. The causes of many of these issues are not well understood. We demonstrate a microneedle device that is several times faster than state of the art, collecting an average of 15.5 mg of ISF in 5 minutes in humans with near-zero failure rate. This improvement was achieved by designing the spatial pressure gradient driving ISF flow. The influence of penetration depth, collection time, pressure, and age on ISF collection was elucidated, with Darcy’s law explaining multiple observations. A data-driven acceptance criterion of <1% blood contamination for ISF is proposed. The device and findings presented will empower researchers to better conduct robust studies in the development of ISF diagnostics.

15 March 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
AHAndy H. Hung
Andy H. Hung
NRNetra U. Rajesh
Netra U. Rajesh
ABAbel Bermudez
Abel Bermudez
SBStephanie M. Boczek
Stephanie M. Boczek
FGFernando J. Garcia-Marqués
Fernando J. Garcia-Marqués
JDJoseph M. DeSimone
Joseph M. DeSimone
Dermal interstitial fluid (ISF) offers a promising alternative to invasive blood tests and opportunities for novel skin diagnostics. Progress in both the understanding and adoption of ISF tests is hindered by sampling challenges, including lengthy collection times, non-negligible failure rates, variable collection volumes, and inconsistent bioanalyte levels. The causes of many of these issues are not well understood. We demonstrate a microneedle device that is several times faster than state-of-the-art, collecting an average of 15.5 mg of ISF in 5 minutes in humans with near-zero failure rate. This improvement was achieved by designing the spatial pressure gradient driving ISF flow. The influence of penetration depth, collection time, pressure, and age on ISF collection was elucidated, with Darcy’s law explaining multiple observations. A data-driven acceptance criterion of <1% blood contamination for ISF is proposed. The device and findings presented will empower researchers to better conduct robust studies in the development of ISF diagnostics.

7 February 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
ICIan A. Coates
Ian A. Coates
MDMadison M. Driskill
Madison M. Driskill
NRNetra U. Rajesh
Netra U. Rajesh
GLGabriel Lipkowitz
Gabriel Lipkowitz
DIDan Ilyin
Dan Ilyin
JDJoseph M. DeSimone
Joseph M. DeSimone
Personalized biomedical devices, such as microneedle array patches (MAPs), offer a promising transdermal drug delivery technology, providing a safe, painless, and self- administered alternative to traditional hypodermic injections. Despite their potential for precise therapeutic release, MAP adoption has been limited by challenges in payload capacity, treatment versatility, and manufacturing scalability. To address these issues, we integrated microfluidic channel designs with MAP technology, enhancing its functionality for delivering a range of payloads, from liquid therapeutics to solid-state cargos, at tunable volumes. Using injection continuous liquid interface production (iCLIP), a novel additive manufacturing approach, we fabricated high-resolution microfluidic MAPs with complex designs. Inspired by the stingers and fangs of various venomous animals, we developed a biomimetic microneedle design that prevents clogging, enhances mechanical strength, and eliminates needle leakage, thereby improving therapeutic delivery efficiency. Our technology reliably delivers multiple distinct payloads, enables combinational mixing, and enables point-of-care reconstitution of solid-state payloads. Teaser Leveraging biomimetic design and advanced 3D printing, we developed high-resolution microfluidic microneedle array patches (MAPs) that overcome payload and scalability challenges, offering a versatile and efficient platform for precise transdermal drug delivery.